HC Wainwright Brokers Lift Earnings Estimates for Vericel Co. (NASDAQ:VCEL)

Vericel Co. (NASDAQ:VCEL) – HC Wainwright raised their Q3 2024 earnings estimates for Vericel in a report released on Thursday, November 9th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.03 per share for the quarter, up from their previous estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $44.50 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Vericel’s FY2024 earnings at $0.30 EPS, FY2025 earnings at $0.93 EPS, FY2026 earnings at $1.25 EPS and FY2027 earnings at $1.90 EPS.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $45.58 million during the quarter, compared to the consensus estimate of $45.14 million. Vericel had a negative net margin of 5.54% and a negative return on equity of 5.19%.

VCEL has been the subject of a number of other reports. Truist Financial increased their price target on shares of Vericel from $33.00 to $39.00 and gave the stock a “hold” rating in a research note on Thursday. Stephens reissued an “overweight” rating and issued a $44.00 price target on shares of Vericel in a research note on Thursday, September 21st. Leerink Partnrs reissued an “outperform” rating on shares of Vericel in a research note on Monday, October 16th. StockNews.com assumed coverage on shares of Vericel in a research note on Thursday, October 5th. They issued a “hold” rating for the company. Finally, BTIG Research raised shares of Vericel from a “neutral” rating to a “buy” rating and set a $39.00 price target for the company in a research note on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.70.

Vericel Trading Up 4.6 %

Shares of NASDAQ:VCEL opened at $33.91 on Friday. Vericel has a 12 month low of $20.40 and a 12 month high of $39.90. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -147.43 and a beta of 1.67. The company has a 50-day moving average price of $34.17 and a 200-day moving average price of $34.29.

Institutional Investors Weigh In On Vericel

Hedge funds and other institutional investors have recently bought and sold shares of the business. ExodusPoint Capital Management LP grew its holdings in Vericel by 191.0% in the first quarter. ExodusPoint Capital Management LP now owns 42,546 shares of the biotechnology company’s stock worth $1,247,000 after purchasing an additional 27,923 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Vericel during the second quarter valued at approximately $1,016,000. Citigroup Inc. grew its holdings in shares of Vericel by 3.9% during the first quarter. Citigroup Inc. now owns 109,391 shares of the biotechnology company’s stock valued at $3,207,000 after buying an additional 4,088 shares during the last quarter. MAI Capital Management grew its holdings in shares of Vericel by 3.6% during the second quarter. MAI Capital Management now owns 12,040 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 415 shares during the last quarter. Finally, Summit Creek Advisors LLC grew its holdings in shares of Vericel by 0.8% during the first quarter. Summit Creek Advisors LLC now owns 433,547 shares of the biotechnology company’s stock valued at $12,712,000 after buying an additional 3,567 shares during the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.